Search

Supernus Pharmaceuticals Inc

Open

SectorHealthcare

41.47 0.95

Overview

Share price change

24h

Current

Min

40.67

Max

41.66

Key metrics

By Trading Economics

Income

-56M

-58M

Sales

11M

219M

EPS

0.39

Profit margin

-26.646

Employees

778

EBITDA

-50M

-30M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+57.56% upside

Dividends

By Acuity

Next Earnings

3 Nov 2026

Market Stats

By TradingEconomics

Market Cap

-313M

2.4B

Previous open

40.52

Previous close

41.47

News Sentiment

By Acuity

50%

50%

134 / 339 Healthcare

Supernus Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Sept 2026, 22:36 UTC

Supernus Pharmaceuticals Inc is declining in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

15 Sept 2026, 20:01 UTC

Supernus Pharmaceuticals Inc shares are lower, extending an eight-session decline. Broader market sentiment is affected by a significant drop in the NY Empire State Manufacturing Index.

14 Sept 2026, 19:36 UTC

Supernus Pharmaceuticals Inc. is trading higher today, despite broader market pressure from rising crude oil prices and geopolitical supply concerns.

11 Sept 2026, 20:13 UTC

Supernus Pharmaceuticals Inc. shares rose in after-market trading, reflecting broader market trends amid recent inflation data and speculation of a Federal Reserve interest rate hike.

10 Sept 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower, continuing a five-session decline amid broader market trends following the European Central Bank's interest rate hike.

8 Sept 2026, 20:02 UTC

Supernus Pharmaceuticals Inc. shares are lower as the Pharmaceuticals sub-sector faces significant declines, continuing a trend from the past three sessions.

2 Sept 2026, 19:36 UTC

Supernus Pharmaceuticals is trading higher Wednesday, despite earlier pulling back from an intraday peak amid broader geopolitical tensions affecting oil prices.

1 Sept 2026, 20:09 UTC

Supernus Pharmaceuticals Inc shares are lower today amid increased market volatility and investor concerns over rising oil prices and potential Federal Reserve interest rate hikes.

31 Aug 2026, 21:02 UTC

Supernus Pharmaceuticals Inc shares are higher in after-market trading, reflecting a notable rise since Monday's close. No specific news was identified to explain the movement.

28 Aug 2026, 19:26 UTC

Supernus Pharmaceuticals Inc. shares are trading lower, continuing a trend of declines amid broader market concerns about inflation and Federal Reserve remarks on price stability.

27 Aug 2026, 20:07 UTC

Supernus Pharmaceuticals Inc shares are declining, continuing a downward trend since Wednesday. Broader market conditions may be contributing to this weakness.

26 Aug 2026, 20:08 UTC

Supernus Pharmaceuticals Inc shares are lower today, driven by declines in the Pharmaceuticals sub-sector. The stock is trading near its one-month low.

25 Aug 2026, 19:16 UTC

Supernus Pharmaceuticals Inc. shares are higher today amid a broader market rally, supported by falling crude oil prices and lower treasury yields.

24 Aug 2026, 19:26 UTC

Supernus Pharmaceuticals Inc. shares are lower, continuing a four-session decline amid broader market volatility and geopolitical tensions affecting oil supply.

21 Aug 2026, 20:01 UTC

Supernus Pharmaceuticals Inc. shares are lower today, aligning with broader market weakness and finishing at the lowest point observed during the session.

20 Aug 2026, 21:01 UTC

Supernus Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of three consecutive daily declines amid broader market pressures.

18 Aug 2026, 19:36 UTC

Supernus Pharmaceuticals Inc is trading higher, maintaining upward momentum since Monday. The stock remains above its 20-day moving average and near a one-month high.

17 Aug 2026, 19:26 UTC

News

Supernus Pharmaceuticals Inc is featured in a cautionary analysis from Yahoo Finance, citing below-average sales growth and declining cash flow margin. The stock is roughly flat today.

14 Aug 2026, 19:16 UTC

Macro Event

Supernus Pharmaceuticals Inc shares are higher, maintaining momentum since Thursday amid broader market caution following a decline in U.S. retail sales.

13 Aug 2026, 19:16 UTC

Supernus Pharmaceuticals Inc shares are lower Thursday, pulling back from an early high. No specific news was identified to explain the movement.

12 Aug 2026, 19:51 UTC

Supernus Pharmaceuticals shares are higher amid positive market sentiment following an inflation report and strength in technology stocks.

11 Aug 2026, 20:01 UTC

Supernus Pharmaceuticals Inc shares are lower as the Pharmaceuticals sector declines. The stock is trading with unusually high volume today.

10 Aug 2026, 22:46 UTC

Supernus Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Monday's close amid broader market reassessments of interest rate hikes.

7 Aug 2026, 19:31 UTC

Supernus Pharmaceuticals Inc. is trading higher, influenced by an advancing overall market amid positive macroeconomic indicators, despite ongoing geopolitical tensions.

6 Aug 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday's close, amid unusually high market volume.

5 Aug 2026, 20:03 UTC

Supernus Pharmaceuticals Inc shares are higher Wednesday, driven by high market volume and broader positive sentiment amid declining oil prices and geopolitical optimism.

4 Aug 2026, 19:51 UTC

News

Supernus Pharmaceuticals is declining following its merger announcement with Indivior and a quarterly revenue report of $219 million amid a net loss of $58 million.

3 Aug 2026, 19:51 UTC

Social Media
News
Event

Supernus Pharmaceuticals announced a merger with Indivior, creating a company with $2.2 billion in revenue. Shares are higher following strong Q2 earnings that beat estimates.

31 Jul 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early gain amid broader market concerns over rising Treasury yields and crude oil prices.

30 Jul 2026, 14:33 UTC

Supernus Pharmaceuticals Inc. shares are lower, impacted by weakness in the pharmaceuticals sub-sector. The stock briefly rebounded earlier in the session before declining.

Peer Comparison

Price change

Supernus Pharmaceuticals Inc Forecast

Price Target

By TipRanks

57.56% upside

12 Months Forecast

Average 65.2 USD  57.56%

High 67 USD

Low 63 USD

Based on 5 Wall Street analysts offering 12 month price targets forSupernus Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Sentiment

By Acuity

134 / 339 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
help-icon Live chat